5 Risperidone and related 5HT2/D2 antagonists: A new type of antipsychotic agent?

Progress in Medicinal Chemistry

Volumn 33, Issue C, 1996, Pages 185-232

  Megens, Anton A H P ^a   Kennis, Ludo E J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; HUMAN; REVIEW; SCHIZOPHRENIA;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR STRUCTURE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0029688430     PISSN: 00796468     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6468(08)70306-0     Document Type: Article

References (113)

1. Janssen P.A.J. J. Drug Ther. Res. 12 (1987) 324-328
2. Meltzer H.Y., and Nash J.F. Pharmacol. Rev. 43 (1991) 587-604
3. Meltzer H.Y., Matsubara S., and Lee J.-C. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
4. Niemegeers C.J.E., Awouters F., and Janssen P.A.J. In: Paoletti R., and Vanhoutte P.M. (Eds). Serotonin: from Cell Biology to Pharmacology and Therapeutics (1990), KJuwer Publishers, Dordrecht 531-541
5. Janssen P.A.J., Niemegeers C.J.E., Awouters F., Schellekens K.H.L., Megens A.A.H.P., and Meert T.F. J. Pharmacol. Exp. Ther. 244 (1988) 685-693
6. Leysen J.E., Gommeren W., Eens A., De Chaffoy De Courcelles D., Stoof J.C., and Janssen P.A.J. J. Pharmacol. Exp. Ther. 247 (1988) 661-670
7. Megens A.A.H.P., Awouters F.H.L., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J.E., and Leysen J.E. Psychopharmacology 114 (1994) 9-23
8. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., and Arnott W. J. Clin. Psychopharmacol. 13 (1993) 25-40
9. Bleuler E. Dementia Praecox or the Group of Schizophrenias. Translation J. Zinkin (1908), International Universities Press, New York
10. S.R. Kay 1991 Positive and Negative Syndromes in Schizophrenia. Clinical and Experimental Psychiatry Monograph No 5. pp. 3-11, Brunner/Mazel, New York
11. McGlashan T. Arch. Gen. Psychiatry 41 (1984) 586-601
12. Prasad A.J., and Kumar N. Suicide Life-Threatening Behav. 18 (1988) 265-269
13. Torrey E.F. Surviving Schizophrenia: A Family Manual (1983), Harper and Row, New York
14. Nimatoudis J., Fotiadis H., Kokantzis N., Karavatos A., and Fotiadou M. In: Stefanis C.N., Soldatos C.R., and Rabavilas A.D. (Eds). Psychiatry today: Accomplishments and Promises (1989), Excerpta Medica, Amsterdam 288
15. Kraepelin E. Krieger (1919), Huntington, New York
16. Strauss J.S., and Carpenter Jr. W.T. Arch. Gen. Psychiatry 27 (1974) 739-745
17. Strauss J.S., Carpenter Jr. W.T., and Bartko J.J. Schizophr. Bull. 11 (1974) 61-76
18. Hughlings-Jackson J. In: Taylor J. (Ed). Selected Writings (1931), Hodder & Stoughton Ltd., London
19. Crow T.J. Br. Med. J. 280 (1980) 66-68
20. Crow T.J. Br. J. Psychiatry 137 (1980) 383-386
21. Andreasen N.C., and Olsen S.A. Arch. Gen. Psychiatry 39 (1982) 789-794
22. Andreasen N.C., Olsen S.A., Dennert J.W., and Smith M.R. Am. J. Psychiatry 139 (1982) 297-302
23. Carpenter Jr. W.T., Heinrichs D.W., and Alphs L.D. Schizophr. Bull. 11 (1985) 440-452
24. Carpenter Jr. W.T., Heinrichs D.W., and Wagman A.M.I. Am. J. Psychiatry 145 (1988) 578-583
25. Hornykiewicz O. Nature (London) 299 (1982) 484 186
26. Hornykiewicz O. Prog. Brain Res. 65 (1986) 29-39
27. De Wied D. Trends NeuroSci. 2 (1979) 79-82
28. Snyder S.H., and Largent B.L. J. Neuropsychiatry 1 (1988) 7-15
29. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., and Rice K.C. Pharmacol. Rev. 42 (1990) 355-402
30. Canton H., Verrielè L., and Colpaert F.C. Eur. J. Pharmacol. 191 (1990) 93-96
31. Roth B.L., Ciaranello R.D., and Meltzer H.Y. J. Pharmacol. Exp. Ther. 260 (1992) 1361-1365
32. DeVeaugh-Geiss J., McBain S., Cooksey P., and Bell J.M. In: Meltzer H.Y. (Ed). Novel Antipsychotic Drugs (1991), Raven Press, New York 225-232
33. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma Jr. F.J., Shen Y., Meltzer H.J., and Sibley D.R. J. Pharmacol. Exp. Ther. 268 (1994) 1403-1410
34. Nair N.P.V., Lai S., and Bloom D.M. Prog. Brain Res. 65 (1986) 237-258
35. Payeur R., Nixon M.K., Bourin M., Bradweijn J., and Legrand J.M. Eur. Psychiatry 8 (1993) 67-78
36. Wang R.Y. Ann. N.Y. Acad. Sci. 537 (1988) 362-379
37. Carlsson M., and Carlsson A. Trends NeuroSci. 13 (1990) 272-276
38. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., and Morihisa J.M. Clin. Neuropharmacol. 12 (1989) 1-13
39. Roberts E. Neurosci. Res. Program Bull. 10 (1972) 468 182
40. Schenk J.O., Morocco M.T., and Ziemba V.A. J. Neurochem. 57 (1991) 1787-1795
41. Witkin J.M. Life Sci. 53 (1993) 405-410
42. Civelli O., Bunzow J.R., and Grandy D.K. Annu. Rev. Pharmacol. Toxicol. 32 (1993) 281-307
43. Grandy D.K., Zhang Y., Bouvier C., Zhou Q.-Y., Johnson R.A., Allen L., Buck K., Bunzow J.R., Salon J., and Civelli O. Physiol. Pharmacol. Physicians 88 (1991) 9175-9179
44. Seeman P. Neuropsychopharmacology 7 (1992) 261-284
45. Seeman P., Guan H.-C., and Van Tol H.H.M. Nature (London) 365 (1993) 441-445
46. Sibley D.R., and Monsma Jr. F.J.A. Trends Pharmacol. Sci. 13 (1992) 61-69
47. Sokoloff P., Martres M.-P., Giros B., Bouthenet M.-L., and Schwartz J.-C. Biochem. Pharmacol. 43 (1992) 659-666
48. Crow T.J., Deakin J.F.W., and Longden A. Psychol. Med. 7 (1977) 213-221
49. Stevens J.R. Arch. Gen. Psychiatry 29 (1973) 177-189
50. Wilk S., Watson E., and Stanley M.E. J. Pharmacol. Exp. Ther. 195 (1975) 265-270
51. Èlander T., Anden N.-E., and Grabowska-Anden M. Naunyn-Schmiedeberg's Arch. Pharmacol. 312 (1980) 145-150
52. Magnusson O., Fowler C.J., Mohringe B., Wijkström A., and ÜOgren S.-O. Naunyn-Schmiedeberg's Arch. Pharmacol. 337 (1988) 379-384
53. Carlsson A. J. Neural Transm. 57 (1983) 309-315
54. Carlsson A., Sen A.K., and Lee T. Receptors and Ligands in Psychiatry (1988), Cambridge University Press, Cambridge 1-10
55. Meltzer H.Y. Schizophr. Bull. 6 (1980) 456-475
56. Roth R.H. Commun. Psychopharmacol. 3 (1979) 429-445
57. Wise L.D., and Jaen J.C. In: Kozikowski A.P. (Ed). Drug Design for Neuroscience (1993), Raven Press, New York 119
58. Snyder S.H., Greenberg D., and Yamamura H.I. J. Psychiatr. Res. 11 (1974) 91-95
59. Lowe J.A. Curr. Med. Chem. 1 (1994) 50-60
60. Leysen J.E., Janssen P.M.F., Schotte A., Luyten W.H.M.L., and Megens A.A.H.P. in Serotonin, Dopamine and their Interactions in Schizophrenia (Kahn, R.S. and Davidson, M., ed.) Psychopharmacology 112 (1993) S40-S54
61. Leysen J.E., Janssen P.M.F., Gommeren W., Wynants J., Pauwels P.P., and Janssen P.A.J. Mol. Pharmacol. 41 (1992) 494-508
62. Kennis L.E.J., Vandenberk J., Boey J.M., Mertens J.C., Van Heertum A.H.M., Janssen M., and Awouters F. Drug Dev. Res. 8 (1986) 133-140
63. Niemegeers C.J.E., Lenaerts F.M., Artois K.S.K., and Janssen P.A.J. Arch. Int. Pharmacodyn. Ther. 227 (1977) 238-253
64. Niemegeers C.J.E. Psychopharmacology 78 (1982) 210-213
65. Finney D.J. Probit Analysis. 3rd edition (1980), Cambridge University Press, London 50-80 chapter 4
66. Delay J., Deniker P., and Harl J.M. Ann. Med. Psychol. 110 (1952) 112-117
67. Tedeschi D.H., Tedeschi R.E., and Fellows E.J. Arch. Int. Pharmacodyn. Ther. 132 (1961) 172-179
68. Woolley D.W. The Biochemical Bases of Psychoses or the Serotonin Hypothesis about Mental Diseases (1962), John Wiley, New York 131
69. Janssen P.A.J., and Niemegeers C.J.E. Arzneim.-Forsch. 9 (1959) 765-767
70. Janssen P.A.J., Niemegeers C.J.E., and Schellekens K.H.L. Arzneim.-Forsch. 10 (1960) 1003-1005
71. Divry P., Bobon J., Collard J., Pinchard A., and Nols E. Acta Neurol. Psychiatry Belg. 59 (1959) 337-366
72. Janssen P.A.J., Niemegeers C.J.E., and Schellekens K.H.L. Arzneim.-Forsch. 15 (1965) 104-117
73. Janssen P.A.J., Niemegeers C.J.E., and Schellekens K.H.L. Arzneim.-Forsch. 15 (1965) 1196-1206
74. Janssen P.A.J., Niemegeers C.J.E., and Schellekens K.H.L. Arzneim.-Forsch. 16 (1966) 339-346
75. Janssen P.A.J., Niemegeers C.J.E., Schellekens K.H.L., and Lenaerts F.M. Arzneim.-Forsch. 17 (1967) 841-854
76. Janssen P.A.J., and Awouters F.H.L. Arzneim.-Forsch. 44 (1994) 269-277
77. Meltzer H.Y., and Stahl S.M. Schizophr. Bull. 2 (1976) 19-76
78. Niemegeers C.J.E., and Janssen P.A.J. Life Sci. 24 (1979) 2201-2216
79. Ansoms C., De Backer-Dierick C., and Vereecken J.T.L.M. Acta Psychiatr. Scand. 55 (1977) 116-122
80. Deberdt R. Acta Psychiatr. Belg. 76 (1976) 157-166
81. Gerlach J., Thorsen K., and Fog R. Psychopharmacology 40 (1975) 341-350
82. Malsch U. Therapiewoche 37 (1987) 2484-2487
83. Povlsen U.J., Noring U., Fog R., and Gerlach J. Acta Psychiatr. Scand. 71 (1985) 176-185
84. Simpson G.M., and Varga E. Curr. Ther. Res. 16 (1974) 679-686
85. Reyntjens A., Gelders Y.G., Hoppenbrouwers M.-L.J.A., and Van Den Bussche G. Drug Dev. Res. 8 (1986) 205-211
86. Ceulemans D.L.S., Gelders Y.G., Hoppenbrouwers M.-L.J.A., Reyntjens A.J.M., and Janssen P.A.J. Psychopharmacology 85 (1985) 329-332
87. Megens A.A.H.P., and Awouters F.H.L. Drug Dev. Res. 33 (1994) 399 112
88. Van Beijsterveldt L.E.C., Geerts R.J.F., Leysen J.E., Megens A.A.H.P., Van den Eynde H.M.J., Meuldermans W.E.G., and Heykants J.J.P. Psychopharmacology 114 (1994) 53-62
89. Leysen J.E., Gommeren W., Wynants J., Mertens J., Luyten W.H.M.L., Pauwels P.J., Ewert M., and Seeburg P. Psychopharmacology 110 (1993) 27-36
90. Schotte A., de Bruyckere K., Janssen P.F.M., and Leysen J.E. Brain Res. 500 (1989) 295-301
91. Schotte A., Janssen P.A.J., Megens A.A.H.P., and Leysen J.E. Brain Res. 631 (1993) 191-202
92. Bowden C.R., Voina S.J., Woestenborghs R., De Coster R., and Heykants J. J. Pharmacol. Exp. Ther. 262 (1992) 699-706
93. Hommer D.W., Zahn T.P., Dickar D., and Van Kammen D.P. Psychiatr. Res. 11 (1984) 193-204
94. Jaffe J.H. In: Goodman L.S., and Gilman A. (Eds). The Pharmacological Basis of Therapeutics. 7th ed. (1985), Macmillan, New York 532-581
95. Meert T.F., de Haes P., and Janssen P.A.J. Psychopharmacology 97 (1989) 206-212
96. Meert T.F., de Haes P., Vermote P.C.M., and Janssen P.A.J. Drug Dev. Res. 19 (1990) 353-373
97. Meert T.F. In: Glennon R.A., Järbe T.U.C., and Frankenheim J. (Eds). Drug Discrimination: Applications to Drug Abuse Research (1991), National Institute on Drug Abuse, Rockville 307-323 Research Monograph 116
98. Dugovic C., Wauquier A., and Janssen P.A.J. Neuropharmacology 28 (1989) 1431-1433
99. Hiatt J.F., Floyd T.C., Katz P.H., and Feinberg I. Arch. Gen. Psychiatry 42 (1985) 797-802
100. Megens A.A.H.P., Awouters F.H.L., and Niemegeers C.J.E. Psychopharmacology 95 (1988) 493-496
101. Megens A.A.H.P., Awouters F.H.L., and Niemegeers C.J.E. Drug Dev. Res. 17 (1989) 23-33
102. Megens A.A.H.P., Niemegeers C.J.E., and Awouters F.H.L. Drug Dev. Res. 26 (1992) 129-145
103. Megens A.A.H.P., Niemegeers C.J.E., and Awouters F.H.L. J. Pharmacol. Exp. Ther. 260 (1992) 160-167
104. Awouters F.H.L., Niemegeers C.J.E., Megens A.A.H.P., and Janssen P.A.J. J. Pharmacol. Exp. Ther. 254 (1990) 945-951
105. Meert T.F., Niemegeers C.J.E., Awouters F., and Janssen P.A.J. Drug Dev. Res. 13 (1988) 237-244
106. Niemegeers C.J.E., and Janssen P.A.J. In: Fielding S., and Lai H. (Eds). Industrial Pharmacology. Part II. Antidepressants (1975), Futura Publishing Company, New York 125-141
107. Corbet R., Hartman H., Kerman L.L., Woods A.T., Strupczewski J.T., Helsley G.C., Conway P.C., and Dunn R.W. Pharmacol. Biochem. Behav. 45 (1993) 9-17
108. Crow T.J., Deakin J.F.W., and Longden A. Psychol. Med. 7 (1977) 213-221
109. Largent B.L., Gundlach A.L., and Snyder S.H. J. Pharmacol. Exp. Ther. 238 (1986) 739-748
110. Devaud L.L., and Hollingsworth E.B. Eur. J. Pharmacol. 192 (1991) 427-429
111. Saller C.F., Czupryna M.J., and Salama A.I. J. Pharmacol. Exp. Ther. 253 (1990) 1162-1170
112. T.H. Svensson, G.G. Nomikos, J.L. Andersson, 1993) Proc. 2nd Int. Symposium on Serotonin from Cell Biology to Pharmacology and Therapeutics, Houston, Texas, USA, September 15-18, 1992 in 2nd Serotonin from Cell Biology to Pharmacology and Therapeutics (Paoletti, R., Saxena, P. and Vanhoutte, P., eds.) pp. 263-270, Kluwer Academic Publishers, Dordrecht.
113. Perregaard J., Arnt J., Bøgesø K.P., Hyttel J., and Sanchez C.J. J. Med. Chem. 35 (1992) 1092-1101